Welcome to the Empowered Patient Podcast with Karen Jagoda. This show is a window into the latest innovations in applying generative AI, novel therapeutics and vaccines, and the changing dynamics in the medical and healthcare environment. One focus is on how providers, pharmaceutical companies, and payers are empowering patients. In addition, conversations are often about how providers, care facilities, pharmaceutical companies, and payers are being empowered by technology to improve patient outcomes and reduce friction across the healthcare landscape.
Popular Topics
- Virtual and digital health
- Use of AI, ML, and LLM in healthcare and drug discovery, development, trials
- Value-based healthcare
- Precision and stratified medicine
- Integration of digital technology into existing workflow and procedures
- Next-generation immuno, cell, and gene therapies
- Vaccines
- Biomarkers, sequencing, and imaging
- Rare diseases
- MedTech and medical devices
- Clinical trials
- Addressing Social Determinants of Health
- Treating chronic conditions like obesity and pain
- Clinician and staff burnout
The audience includes life science leaders, researchers, medical professionals, patient advocates, digital health entrepreneurs, patients, caregivers, healthcare solution providers, students, journalists, and investors.
Check out our new EmpoweredPatient.Solutions site where you can quickly search all of the Empowered Patient Podcast interviews by any word or phrase to identify useful resources, potential partners, and insights about the life sciences landscape.
Cell Therapies Drive Immune System in Cures for Solid Tumors and Blood Cancers with Alain Maiore Mnemo Therapeutics TRANSCRIPT
Download PDFAug 2, 2021
Alain Maiore is the Co-Founder and CEO of Mnemo Therapeutics and has a mission to change the future of cell therapy. The Mnemo platform EnfiniT is an integrated drug discovery engine that combines T-cell engineering technologies with greater target identification to transform the body's immune response to overcome currently incurable diseases.
Mnemo has just raised $90 million in a Series A round, the largest round to date in France.
Alain says, "I think our job is to make sure that whatever technology we put together, everyone that is in need of having access to these drugs gets access to these drugs. So it is our responsibility to combine the technologies and medical development and the manufacturing of these drugs so that we can size the necessity of financial performance and shoulder reward with accessibility to every patient. That responsibility is increasingly important in the world that is opening to us."
@MnemoTx #MnemoTherapeutics #EnfiniT #Cancer #BloodCancer #CellTherapies #SolidTumors #DrugTargeting #TCells #Immunetherapies #epigenetics #CarTCells
